Symbiotec Subsidiary Knovea Signs US DCV Agreement

Date: September 30, 2026

Not Specified

Not Specified

Not Specified

Not Specified

Strategic Commercialization Agreement Details:

Knovea Pharmaceutical Pvt. Ltd. (wholly owned subsidiary of Symbiotec Pharmalab Limited) entered definitive agreement with a leading global pharmaceutical company
Agreement grants exclusive rights to commercialize and distribute two Dual Chamber Vial (DCV)-based injectable products in the United States
Knovea will lead development, regulatory submissions, manufacturing and supply
Partner will drive commercialization and distribution across the U.S.
Collaboration includes milestone payments through development, regulatory approval and commercial launch
Profit-sharing arrangement from launch onwards
Two products address U.S. market estimated at approximately US$288 million
DCV technology keeps drug and diluent separate until combined at point of care, protecting stability of sensitive formulations

Annexure A Disclosures:

Acquisition does not fall within related party transactions
Promoter/promoter group/group companies have no interest in the entity being acquired
Transaction is not applicable for arm's length assessment
Size of the entity cannot be disclosed due to confidentiality obligations
Rationale: Agreement marks decisive step in commercialization of Knovea's DCV platform
Benefit: Strengthens Knovea's position in high-value complex injectables segment and opens door to further partnerships across products benefiting from Knovea's differentiated drug-delivery and reconstitution technologies

Regulatory Compliance:

Filed pursuant to Regulation 30 read with Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Includes details required under SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026